<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465138</url>
  </required_header>
  <id_info>
    <org_study_id>15-16365</org_study_id>
    <nct_id>NCT02465138</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis</brief_title>
  <official_title>A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine if IV ketorolac is an effective agent in the prevention of post-ERCP pancreatitis.
      Determine if IV ketorolac provides improved post-procedure analgesia.

      Determine if systemic mediators of inflammation are reduced in patients receiving IV
      ketorolac following ERCP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute pancreatitis is the most common major complication of both diagnostic and therapeutic
      endoscopic retrograde cholangiopancreatography (ERCP), accounting for substantial morbidity
      and an annual expenditure of approximately 150 million annually.(1,2) Non-steroidal
      anti-inflammatory agents (NSAIDs) have been shown to be effective in multiple prospective
      randomized controlled trial for the prevention of post-ERCP pancreatitis.(3-6) NSAIDs are
      postulated to inhibit phospholipase A2 and prostaglandin synthesis, which plays an important
      role in the inflammatory cascade in acute pancreatitis. Rectal suppository indomethacin (a
      potent COX-2 inhibitor) has been effective in preventing post-ERCP pancreatitis in clinical
      trials and is now recommended for routine use for ERCP by the European Society of
      Gastrointestinal Endoscopy.(7) Toradol® (ketorolac), an NSAID available in IV form, is a more
      potent COX-2 inhibitor and analgesic than indomethacin.(8,9) Ketorolac is routinely used
      postoperatively following major surgery to assist in pain control particularly following
      orthopedic procedures. IV ketorolac has never been evaluated for the prevention of post-ERCP
      pancreatitis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>5 days after ERCP procedure</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline will be administered prior to procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toradol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous ketorolac prior to ERCP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Intravenous ketorolac</description>
    <arm_group_label>Toradol</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients presenting to SFGH for ERCP

          -  Age 18-85

          -  Do not meet exclusion criteria

        Exclusion Criteria:

          -  Acute pancreatitis at the time of ERCP

          -  Use of NSAIDs in the previous week

          -  Peptic ulcer disease

          -  Severe renal dysfunction

          -  Pregnancy

          -  Lithium therapy

          -  allergy to ketorolac
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Cello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John P Cello, MD</last_name>
    <phone>415-206-4767</phone>
    <email>john.cello@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stanley J Rogers, MD</last_name>
    <phone>415-476-0762</phone>
    <email>stan.rogers@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alex Rodas</last_name>
      <email>arodas@medsfgh.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Anupam Aditi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John P Cello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stanley J Rogers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF/San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94132/94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004 Jun;59(7):845-64. Review.</citation>
    <PMID>15173799</PMID>
  </results_reference>
  <results_reference>
    <citation>Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, Moore JP, Fennerty MB, Ryan ME, Shaw MJ, Lande JD, Pheley AM. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996 Sep 26;335(13):909-18.</citation>
    <PMID>8782497</PMID>
  </results_reference>
  <results_reference>
    <citation>Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, Hayward RA, Romagnuolo J, Elta GH, Sherman S, Waljee AK, Repaka A, Atkinson MR, Cote GA, Kwon RS, McHenry L, Piraka CR, Wamsteker EJ, Watkins JL, Korsnes SJ, Schmidt SE, Turner SM, Nicholson S, Fogel EL; U.S. Cooperative for Outcomes Research in Endoscopy (USCORE). A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012 Apr 12;366(15):1414-22. doi: 10.1056/NEJMoa1111103.</citation>
    <PMID>22494121</PMID>
  </results_reference>
  <results_reference>
    <citation>Otsuka T, Kawazoe S, Nakashita S, Kamachi S, Oeda S, Sumida C, Akiyama T, Ario K, Fujimoto M, Tabuchi M, Noda T. Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J Gastroenterol. 2012 Aug;47(8):912-7. doi: 10.1007/s00535-012-0554-7. Epub 2012 Feb 18.</citation>
    <PMID>22350703</PMID>
  </results_reference>
  <results_reference>
    <citation>Sotoudehmanesh R, Khatibian M, Kolahdoozan S, Ainechi S, Malboosbaf R, Nouraie M. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol. 2007 May;102(5):978-83. Epub 2007 Mar 13.</citation>
    <PMID>17355281</PMID>
  </results_reference>
  <results_reference>
    <citation>Khoshbaten M, Khorram H, Madad L, Ehsani Ardakani MJ, Farzin H, Zali MR. Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 2):e11-6. Epub 2007 Aug 7.</citation>
    <PMID>17683501</PMID>
  </results_reference>
  <results_reference>
    <citation>Dumonceau JM, Andriulli A, Deviere J, Mariani A, Rigaux J, Baron TH, Testoni PA; European Society of Gastrointestinal Endoscopy. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. Endoscopy. 2010 Jun;42(6):503-15. doi: 10.1055/s-0029-1244208. Epub 2010 May 26.</citation>
    <PMID>20506068</PMID>
  </results_reference>
  <results_reference>
    <citation>Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998 May;104(5):413-21.</citation>
    <PMID>9626023</PMID>
  </results_reference>
  <results_reference>
    <citation>Gillis JC, Brogden RN. Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs. 1997 Jan;53(1):139-88. Review.</citation>
    <PMID>9010653</PMID>
  </results_reference>
  <results_reference>
    <citation>Gross V, Leser HG, Heinisch A, Schölmerich J. Inflammatory mediators and cytokines--new aspects of the pathophysiology and assessment of severity of acute pancreatitis? Hepatogastroenterology. 1993 Dec;40(6):522-30. Review.</citation>
    <PMID>7509768</PMID>
  </results_reference>
  <results_reference>
    <citation>Bhatia M, Brady M, Shokuhi S, Christmas S, Neoptolemos JP, Slavin J. Inflammatory mediators in acute pancreatitis. J Pathol. 2000 Feb;190(2):117-25. Review.</citation>
    <PMID>10657008</PMID>
  </results_reference>
  <results_reference>
    <citation>Mäkelä A, Kuusi T, Schröder T. Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest. 1997 Aug;57(5):401-7.</citation>
    <PMID>9279965</PMID>
  </results_reference>
  <results_reference>
    <citation>Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003 Jun;124(7):1786-91.</citation>
    <PMID>12806612</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheon YK, Cho KB, Watkins JL, McHenry L, Fogel EL, Sherman S, Schmidt S, Lazzell-Pannell L, Lehman GA. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. Gastrointest Endosc. 2007 Dec;66(6):1126-32.</citation>
    <PMID>18061712</PMID>
  </results_reference>
  <results_reference>
    <citation>Senol A, Saritas U, Demirkan H. Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. World J Gastroenterol. 2009 Aug 28;15(32):3999-4004.</citation>
    <PMID>19705494</PMID>
  </results_reference>
  <results_reference>
    <citation>Döbrönte Z, Toldy E, Márk L, Sarang K, Lakner L. [Effects of rectal indomethacin in the prevention of post-ERCP acute pancreatitis]. Orv Hetil. 2012 Jun 24;153(25):990-6. doi: 10.1556/OH.2012.29403. Hungarian.</citation>
    <PMID>22714033</PMID>
  </results_reference>
  <results_reference>
    <citation>Helleberg L. Clinical Pharmacokinetics of indomethacin. Clin Pharmacokinet. 1981 Jul-Aug;6(4):245-58.</citation>
    <PMID>7249487</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2015</study_first_submitted>
  <study_first_submitted_qc>June 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>John P. Cello, M.D.</investigator_full_name>
    <investigator_title>Professor of Medicine and Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

